Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate …………… Zimmermann TS, Karsten V, Chan A, Chiesa J, Boyce M, Bettencourt BR, Hutabarat R, Nochur S, Vaishnaw A, Gollob J. MolTher. 2017 Jan 4;25(1):71-78. PubMed 00
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 …………… Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A. N Engl J Med. 2017 Jan 5;376(1):41-51. PubMed 00
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial …………… van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J, van Nuenen AC, Beuers U, Hadi S, Harbers M, van der Veer E,…
SPSB1-mediated HnRNP A1 ubiquitylation regulates alternative splicing and cell migration in EGF signaling …………… Wang F, Fu X, Chen P, Wu P, Fan X, Li N, Zhu H, Jia TT, Ji H, Wang Z, Wong CC, Hu R, Hui J. Cell Res. 2017 Jan 13. PubMed 00